Page 32 - 2022-27-中国全科医学

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·3357·

et al. Ustekinumab is associated with superior effectiveness outcomes Therapeutic drug monitoring of biologics during induction to prevent
compared to vedolizumab in Crohn's disease patients with prior primary non-response［J］. J Crohns Colitis，2020，14（4）：
failure to anti-TNF treatment［J］. Aliment Pharmacol Ther， 542-556. DOI：10.1093/ecco-jcc/jjz162.
2020，52（1）：123-134. DOI：10.1111/apt.15745. ［40］COLOMBEL J F，SANDBORN W J，REINISCH W，et al.
［28］BUISSON A，NANCEY S，MANLAY L，et al. Ustekinumab is Infliximab，azathioprine，or combination therapy for Crohn's
more effective than azathioprine to prevent endoscopic postoperative disease［J］. N Engl J Med，2010，362（15）：1383-1395.
recurrence in Crohn's disease［J］. United European Gastroenterol J， DOI：10.1056/NEJMoa0904492.
2021，9（5）：552-560. DOI：10.1002/ueg2.12068. ［41］PANACCIONE R，GHOSH S'MIDDLETON S，et al. Combination
［29］PAPAMICHAEL K，GILS A，RUTGEERTS P，et al. Role for therapy with infliximab and azathioprine is superior to monotherapy
therapeutic drug monitoring during induction therapy with TNF with either agent in ulcerative colitis［J］. Gastroenterology，
antagonists in IBD：evolution in the definition and management of 2014，146（2）： 392-400.e 3. DOI：10.1053/ j .
primary nonresponse［J］. Inflamm Bowel Dis，2015，21（1）： gastro.2013.10.052.
182-197. DOI：10.1097/MIB.0000000000000202. ［42］YZET C，DIOUF M，SINGH S，et al. No benefit of concomitant
［30］WONG U，CROSS R K. Primary and secondary nonresponse to immunomodulator therapy on efficacy of biologics that are not tumor
necrosis factor antagonists in patients with inflammatory bowel
infliximab：mechanisms and countermeasures［J］. Expert Opin
diseases：a meta-analysis［J］. Clin Gastroenterol Hepatol，
Drug Metab Toxicol，2017，13（10）：1039-1046. DOI：
2021，19（4）：668-679.e8. DOI：10.1016/j.cgh.2020.06.071.
10.1080/17425255.2017.1377180.
［43］FUMERY M，PEYRIN-BIROULET L，NANCEY S，et al.
［31］YANG H S，LI B Y，GUO Q，et al. Systematic review with meta-
Effectiveness and safety of ustekinumab intensification at 90 Mg
analysis：loss of response and requirement of ustekinumab dose
every four weeks in Crohn's disease：a multicenter study［J］. J
escalation in inflammatory bowel diseases［J］. Aliment Pharmacol
Crohns Colitis， 2020：2020Sep8；jjaa177. DOI：10.1093/ecco-
Ther，2022，55（7）： 764-777. DOI：10.1111/apt.16802.
jcc/jjaa177.
［32］LIEFFERINCKX C，VERSTOCKT B，GILS A，et al. Long-term
［44］SEDANO R，GUIZZETTI L，MCDONALD C，et al. Intravenous
clinical effectiveness of ustekinumab in patients with Crohn's disease
ustekinumab reinduction is effective in prior biologic failure Crohn's
who failed biologic therapies：a national cohort study［J］. J Crohns
disease patients already on every-4-week dosing［J］. Clin
Colitis，2019，13（11）：1401-1409. DOI：10.1093/ecco-
Gastroenterol Hepatol，2021，19（7）： 1497-1498.e1. DOI：
jcc/jjz080.
10.1016/j.cgh.2020.07.064.
［33］BEN-HORIN S，CHOWERS Y. Tailoring anti-TNF therapy
［45］DALAL R S，NJIE C，MARCUS J，et al. Predictors of ustekinumab
in IBD： drug levels and disease activity［J］. Nat Rev
failure in Crohn's disease after dose intensification［J］. Inflamm
Gastroenterol Hepatol，2014，11（4）： 243-255. DOI：
Bowel Dis，2021，27（8）：1294-1301. DOI：10.1093/ibd/
10.1038/nrgastro.2013.253.
izaa282.
［34］UNGAR B，LEVY I，YAVNE Y，et al. Optimizing anti-
［46］AHMED W，GALATI J，KUMAR A，et al. Dual biologic or small
TNF-α therapy：serum levels of infliximab and adalimumab are
molecule therapy for treatment of inflammatory bowel disease：
associated with mucosal healing in patients with inflammatory bowel
a systematic review and meta-analysis［J］. Clin Gastroenterol
diseases［J］. Clin Gastroenterol Hepatol，2016，14（4）：550-
Hepatol，2022，20（3）：e361-379. DOI：10.1016/j.
557.e2. DOI：10.1016/j.cgh.2015.10.025.
cgh.2021.03.034.
［35］UNGAR B，CHOWERS Y，YAVZORI M，et al. The temporal
［47］YANG E，PANACCIONE N，WHITMIRE N，et al. Efficacy and
evolution of antidrug antibodies in patients with inflammatory bowel
safety of simultaneous treatment with two biologic medications in
disease treated with infliximab［J］. Gut，2014，63（8）： refractory Crohn's disease［J］. Aliment Pharmacol Ther，2020，
1258-1264. DOI：10.1136/gutjnl-2013-305259. 51（11）： 1031-1038. DOI：10.1111/apt.15719.
［36］YAO J Y，ZHANG M，WANG W，et al. Ustekinumab trough ［48］BATTAT R，KOPYLOV U，SZILAGYI A，et al. Vitamin B 12 deficiency
concentration affects clinical and endoscopic outcomes in patients in inflammatory bowel disease： prevalence，risk factors，
with refractory Crohn's disease：a Chinese real-world study［J］. evaluation，and management［J］. Inflamm Bowel Dis，2014，20
BMC Gastroenterol，2021，21（1）：380. DOI：10.1186/ （6）： 1120-1128. DOI：10.1097/MIB.0000000000000024.
s12876-021-01946-8. ［49］BATTAT R，DUIJVESTEIN M，VANDE CASTEELE N，
［37］HANZEL J，ZDOVC J，KURENT T，et al. Peak concentrations et al. Serum concentrations of 7α-hydroxy-4-cholesten-3-
of ustekinumab after intravenous induction therapy identify patients one are associated with bile acid diarrhea in patients with Crohn's
with Crohn's disease likely to achieve endoscopic and biochemical disease［J］. Clin Gastroenterol Hepatol，2019，17（13）：
remission［J］. Clin Gastroenterol Hepatol，2021，19（1）： 2722-2730.e4. DOI：10.1016/j.cgh.2018.11.012.
111-118.e10. DOI：10.1016/j.cgh.2020.02.033. ［50］LICHTENSTEIN G R，LOFTUS E V，ISAACS K L，et al. ACG
［38］ADEDOKUN O J，XU Z H，GASINK C，et al. Pharmacokinetics clinical guideline：management of Crohn's disease in adults［J］.
and exposure response relationships of ustekinumab in patients Am J Gastroenterol，2018，113（4）：481-517. DOI：
with Crohn's disease［J］. Gastroenterology，2018，154（6）： 10.1038/ajg.2018.27.
1660-1671. DOI：10.1053/j.gastro.2018.01.043. （收稿日期：2022-05-30；修回日期：2022-07-13）
［39］SPARROW M P，PAPAMICHAEL K，WARD M G，et al. （本文编辑：李婷婷）